Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

Durrant, Simon TNagler, ArnonGuglielmelli, PaolaLavie, Davidle Coutre, PhilippGisslinger, HeinzChuah, CharlesMaffioli, MargheritaBharathy, SavitaDong, TuochuanWroclawska, MonikaMartinez-Lopez, Joaquin2019-09-102019-09-102019-05-09Haematologica. 2019 May 9. [Epub ahead of print]0390-6078http://hdl.handle.net/20.500.12105/8323engVoRhttp://creativecommons.org/licenses/by-nc-sa/4.0/JAK inhibitorMyelofibrosisRuxolitinibResults from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosisAtribución-NoComercial-CompartirIgual 4.0 Internacional31073072haematol.2018.20996510.3324/haematol.2018.2099651592-8721Haematologicaopen access